Drug intelligence / Profile preview

OPF-501C

Development stage: Unknown
Lead developer: Otsuka Pharmaceutical Factory, Inc.
Modality: Small Molecules
Administration: Topical

Overview

**OPF-501C** is an investigational topical zinc chloride-based treatment developed by Otsuka Pharmaceutical Factory for local control of oozing bleeding associated with cancerous skin ulcers. It was evaluated in a multicenter, open-label, uncontrolled Phase II exploratory study in Japan, in which topical application was associated with immediate suppression of oozing bleeding; the study was completed in May 2024. Development for cancerous skin ulcers was subsequently discontinued. ([jrct.mhlw.go.jp](https://jrct.mhlw.go.jp/en-latest-detail/jRCT2051230016))

Beyond the preview

Go deeper on OPF-501C.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OPF-501C.

Explore the full profile